News from resverlogix corp A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

( OTC-BB:XPWR)

Sep 02, 2014, 16:06 ET
Sep 02, 2014, 14:51 ET

RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 %

Vorgestellt in der "State of the Art and Featured Research Session" beim Kongress des europäischen Kardiologenverbandes...

Sep 02, 2014, 08:30 ET

RVX-208 Leads to a 77% Relative Risk Reduction of Major Adverse Cardiovascular Events (MACE) in Patients with Diabetes Mellitus

Presented in 'State of the Art and Featured Research Session' at the 2014 European Society of Cardiology Congress TSX Exchange Symbol:...

Aug 15, 2014, 17:00 ET

Resverlogix Corp. Closes Additional $30 million from Citibank Loan

TSX Exchange Symbol: RVX CALGARY, Aug. 15, 2014 /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that it has closed...

Aug 13, 2014, 17:01 ET

Resverlogix Corp. Shareholders Approve Additional $30 million from Citibank Loan

TSX Exchange Symbol: RVX CALGARY, Aug. 13, 2014 /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that holders...

Jul 24, 2014, 07:36 ET

RVX-208 reduce los principales efectos secundarios cardiovasculares de la diabetes mellitus

  - RVX-208 reduce significativamente los principales efectos secundarios cardiovasculares (MACE) en pacientes con diabetes...

Jul 23, 2014, 09:00 ET

RVX-208 Reduces Major Adverse Cardiovascular Events (MACE) Significantly in Patients with Diabetes Mellitus

In addition, preliminary results from an Australian sponsored trial have yet to verify whether the mechanism of RVX-208 action may affect glucose...

Jul 03, 2014, 19:21 ET

Resverlogix Secures an Additional $30 million from Citibank Loan

Special Meeting of Shareholders Called to Approve TSX Exchange Symbol: RVX CALGARY, July 3, 2014 /PRNewswire/ - Resverlogix Corp. (TSX:RVX)...

May 21, 2014, 08:00 ET

Leading Life Science Publication SciBX Highlights RVX-208

"Most Advanced Epigenetic Drug in Clinical Development" TSX Exchange Symbol: RVX CALGARY, May 21, 2014 /CNW/ - Resverlogix Corp. ("Resverlogix"...

Mar 31, 2014, 13:00 ET

Cleveland Clinic Presents RVX-208 Data at American College of Cardiology (ACC) Conference in Washington DC March 31, 2014

"RVX-208 decreases Major Adverse Cardiac Events (MACE) in patients with systemic inflammation" TSX Exchange Symbol: RVX CALGARY, March 31,...

Mar 17, 2014, 14:16 ET

Resverlogix Update

"European Patent Office Grants RVX-208 Patent Until 2027" "Resverlogix Receives $2.5 Million for Non-Core ApoA-I Assets" TSX Exchange Symbol:...

Feb 11, 2014, 17:00 ET

Resverlogix Board Update

TSX Exchange Symbol: RVX CALGARY, Feb. 11, 2014 /PRNewswire/ - Resverlogix Corp. (TSX:RVX) announced today that Arthur Higgins will be stepping...

Feb 06, 2014, 16:30 ET

Resverlogix Conference Call & Webcast Announcement

TSX Exchange Symbol: RVX CALGARY, Feb. 6, 2014 /PRNewswire/ - Resverlogix Corp. (TSX:RVX) will be hosting a conference call and webcast on...

Jan 16, 2014, 05:08 ET

Resverlogix anuncia hallazgos combinados de RVX-208 en los ensayos SUSTAIN y ASSURE de fase 2

"RVX-208 presenta una menor incidencia de eventos MACE en los pacientes con alto riesgo de enfermedad cardiovascular." Símbolo de...

Jan 15, 2014, 14:00 ET

Resverlogix Announces Combined RVX-208 findings from SUSTAIN & ASSURE Phase 2b Trials

"RVX-208 treated patients have significant lower MACE events in high risk CVD patients" TSX Exchange Symbol: RVX CALGARY, Jan. 15, 2014...

Jan 02, 2014, 14:53 ET

Publications Confirm RVX-208 is a Unique Selective BET Bromodomain Antagonist

TSX Exchange Symbol: RVX CALGARY, Jan. 2, 2014 /PRNewswire/ - Resverlogix Corp. (TSX: RVX) today announced that a publication titled "RVX-208,...

Dec 23, 2013, 08:00 ET

Resverlogix Completes Enrollment of Phase 2 Clinical Trial of RVX-208 in Patients with Pre-Diabetes Mellitus

TSX Exchange Symbol: RVX CALGARY, Dec. 23, 2013 /PRNewswire/ - Resverlogix Corp. (TSX:RVX) today announced that it has completed enrollment of...

Nov 04, 2013, 08:00 ET

Resverlogix Announces Two New Findings from the ASSURE Trial Relating to Inflammation and Plaque Vulnerability

"RVX-208 lowers Inflammation and MACE Events while Regressing Atheroma in High Risk CVD Patients" TSX Exchange Symbol: RVX CALGARY, Nov. 4,...

Oct 03, 2013, 22:00 ET

Resverlogix Announces Voting Results

TSX Exchange Symbol: RVX CALGARY, Oct. 3, 2013 /PRNewswire/ - Resverlogix Corp. (the "Corporation") (TSX:RVX) today announced that, at its...

Sep 03, 2013, 10:42 ET

Un análisis de datos de ASSURE descubre un grupo de respuesta para RVX-208 con regresión de ateroesclerosis coronaria

- Un análisis superior de los datos de ASSURE descubre un grupo de respuesta para RVX-208 con regresión estadísticamente importante...